Anna Amela Valsecchi, Pamela Festa, Maria Laura Malgarini, Giorgia Novero, Chiara Pallisco, Paola Sabbadini, Silvia Beatrice, Marinella Mistrangelo, Gloria Mittica, Alessandra Beano, Francesco Perrone, Massimo Di Maio
{"title":"Patient-reported financial toxicity within Italian public healthcare system: A cross-sectional analysis in patients with cancer.","authors":"Anna Amela Valsecchi, Pamela Festa, Maria Laura Malgarini, Giorgia Novero, Chiara Pallisco, Paola Sabbadini, Silvia Beatrice, Marinella Mistrangelo, Gloria Mittica, Alessandra Beano, Francesco Perrone, Massimo Di Maio","doi":"10.1177/03008916261417280","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The PROFFIT questionnaire was previously developed and validated, to assess financial toxicity (FT) in Italian patients with cancer. Here we describe FT in patients treated in a public Italian institution in 2024, with a focus on potential determinants of the problem.</p><p><strong>Methods: </strong>PROFFIT was administered cross-sectionally to outpatients undergoing cancer therapy at AOU Città della Salute e della Scienza, Turin. Analysis was descriptive. Multivariate analysis explored association between clinical/demographic features, PROFFIT determinants and PROFFIT score.</p><p><strong>Results: </strong>From October 2024 to December 2024, 359 patients filled in PROFFIT. Median PROFFIT score (0-100 scale) was 33.3 (IQR 14.3-52.4). One hundred and twenty five patients (35%) declared that illness reduced their financial resources. One hundred and three patients (29%) felt that their economic situation affects the possibility of receiving medical care; 124 (35%) felt that National Health Service does not cover all disease costs; 162 (46%) declared payments for private medical exams, 204 (56%) for additional medicines/supplements, 144 (40%) for additional treatments. PROFFIT score was significantly higher in younger patients, in those with worse educational level, in divorced/unmarried patients, in those with economically dependent family members, and in unemployed patients. PROFFIT score was higher for patients with a longer distance to travel to the hospital, although it was not statistically significant. At multivariate analysis, characteristics associated with PROFFIT score were educational level, economically dependent family members, employment status and time from diagnosis; PROFFIT determinants associated with PROFFIT score were payments for additional medicines, payments for additional treatments and travel expenses.ConclusionsEven within the Italian public health system, FT is not negligible among patients with cancer.</p>","PeriodicalId":23349,"journal":{"name":"Tumori","volume":" ","pages":"164-175"},"PeriodicalIF":2.0000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03008916261417280","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: The PROFFIT questionnaire was previously developed and validated, to assess financial toxicity (FT) in Italian patients with cancer. Here we describe FT in patients treated in a public Italian institution in 2024, with a focus on potential determinants of the problem.
Methods: PROFFIT was administered cross-sectionally to outpatients undergoing cancer therapy at AOU Città della Salute e della Scienza, Turin. Analysis was descriptive. Multivariate analysis explored association between clinical/demographic features, PROFFIT determinants and PROFFIT score.
Results: From October 2024 to December 2024, 359 patients filled in PROFFIT. Median PROFFIT score (0-100 scale) was 33.3 (IQR 14.3-52.4). One hundred and twenty five patients (35%) declared that illness reduced their financial resources. One hundred and three patients (29%) felt that their economic situation affects the possibility of receiving medical care; 124 (35%) felt that National Health Service does not cover all disease costs; 162 (46%) declared payments for private medical exams, 204 (56%) for additional medicines/supplements, 144 (40%) for additional treatments. PROFFIT score was significantly higher in younger patients, in those with worse educational level, in divorced/unmarried patients, in those with economically dependent family members, and in unemployed patients. PROFFIT score was higher for patients with a longer distance to travel to the hospital, although it was not statistically significant. At multivariate analysis, characteristics associated with PROFFIT score were educational level, economically dependent family members, employment status and time from diagnosis; PROFFIT determinants associated with PROFFIT score were payments for additional medicines, payments for additional treatments and travel expenses.ConclusionsEven within the Italian public health system, FT is not negligible among patients with cancer.
目的：PROFFIT问卷是先前开发和验证的，用于评估意大利癌症患者的财务毒性（FT）。在这里，我们描述了2024年在意大利一家公共机构接受治疗的患者的FT，重点是问题的潜在决定因素。方法：在都灵AOU citt della Salute e della Scienza接受癌症治疗的门诊患者中横断面给予PROFFIT。分析是描述性的。多变量分析探讨了临床/人口学特征、PROFFIT决定因素和PROFFIT评分之间的关系。结果：2024年10月至2024年12月，359例患者填写了profit。profit评分中位数（0-100分）为33.3 （IQR 14.3-52.4）。125名患者（35%）声称疾病减少了他们的经济资源。103名患者（29%）认为他们的经济状况影响了获得医疗服务的可能性；124个国家（35%）认为国民保健制度没有支付所有疾病费用；162人（46%）宣布支付私人体检费用，204人（56%）支付额外药品/补品费用，144人（40%）支付额外治疗费用。profit评分在年轻患者、受教育程度较低患者、离婚/未婚患者、有经济依赖家庭成员的患者和无业患者中均显著较高。到医院的路程越远，PROFFIT得分越高，尽管没有统计学意义。在多变量分析中，与profit评分相关的特征是受教育程度、经济依赖的家庭成员、就业状况和距离诊断的时间；与PROFFIT评分相关的利润决定因素是额外药物的支付、额外治疗的支付和旅行费用。结论在意大利公共卫生系统中，FT在癌症患者中的作用不容忽视。
期刊介绍：
Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
